StockData
Anixa Biosciences Inc logo

Anixa Biosciences Inc (ANIX) stock

ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 6/30
$2.67+0.12 (+4.71%)

Close on Nov 17, 2026Market cap $92.82MP/E –Yield –

Anixa Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Anixa Biosciences's operating cash flow for the twelve months ending Jul 31, 2026 was -$7.38M. For fiscal 2025 it was -$7.17M. The highest annual figure on record is $1.36M in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Oct 31, 2025-$7.17M–
FY2024Oct 31, 2024-$7.34M–
FY2023Oct 31, 2023-$6.21M–
FY2022Oct 31, 2022-$6.49M–
FY2021Oct 31, 2021-$4.94M–
FY2020Oct 31, 2020-$6.18M–
FY2019Oct 31, 2019-$4.74M–
FY2018Oct 31, 2018-$4.27M–
FY2017Oct 31, 2017-$3.80M–
FY2016Oct 31, 2016-$3.38M-348.0%
FY2015Oct 31, 2015$1.36M–
FY2014Oct 31, 2014-$2.38M–
FY2013Oct 31, 2013-$3.19M–
FY2012Oct 31, 2012-$3.14M–
FY2011Oct 31, 2011-$716.00K–
FY2010Oct 31, 2010-$2.41M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jul 31, 2026-$1.77M–
Q2 FY2026CQ1 2026Apr 30, 2026-$1.74M–
Q1 FY2026CQ4 2025Jan 31, 2026-$2.61M–
Q4 FY2025CQ3 2025Oct 31, 2025-$1.26M–
Q3 FY2025CQ2 2025Jul 31, 2025-$1.51M–
Q2 FY2025CQ1 2025Apr 30, 2025-$1.50M–
Q1 FY2025CQ4 2024Jan 31, 2025-$2.90M–
Q4 FY2024CQ3 2024Oct 31, 2024-$927.00K–
Q3 FY2024CQ2 2024Jul 31, 2024-$2.64M–
Q2 FY2024CQ1 2024Apr 30, 2024-$1.46M–
Q1 FY2024CQ4 2023Jan 31, 2024-$2.31M–
Q4 FY2023CQ3 2023Oct 31, 2023-$1.97M–
Q3 FY2023CQ2 2023Jul 31, 2023-$1.45M–
Q2 FY2023CQ1 2023Apr 30, 2023-$807.00K–
Q1 FY2023CQ4 2022Jan 31, 2023-$1.99M–
Q4 FY2022CQ3 2022Oct 31, 2022-$1.59M–
Q3 FY2022CQ2 2022Jul 31, 2022-$1.40M–
Q2 FY2022CQ1 2022Apr 30, 2022-$2.31M–
Q1 FY2022CQ4 2021Jan 31, 2022-$1.20M–
Q4 FY2021CQ3 2021Oct 31, 2021-$1.05M–
Q3 FY2021CQ2 2021Jul 31, 2021-$1.48M–
Q2 FY2021CQ1 2021Apr 30, 2021-$1.24M–
Q1 FY2021CQ4 2020Jan 31, 2021-$1.17M–
Q4 FY2020CQ3 2020Oct 31, 2020-$1.41M–
Q3 FY2020CQ2 2020Jul 31, 2020-$1.29M–
Q2 FY2020CQ1 2020Apr 30, 2020-$1.56M–
Q1 FY2020CQ4 2019Jan 31, 2020-$1.91M–
Q4 FY2019CQ3 2019Oct 31, 2019-$1.34M–
Q3 FY2019CQ2 2019Jul 31, 2019-$640.10K–
Q2 FY2019CQ1 2019Apr 30, 2019-$1.43M–
Q1 FY2019CQ4 2018Jan 31, 2019-$1.33M–
Q4 FY2018CQ3 2018Oct 31, 2018-$1.02M–
Q3 FY2018CQ2 2018Jul 31, 2018-$1.17M–
Q2 FY2018CQ1 2018Apr 30, 2018-$742.49K–
Q1 FY2018CQ4 2017Jan 31, 2018-$1.34M–
Q4 FY2017CQ3 2017Oct 31, 2017-$739.29K–
Q3 FY2017CQ2 2017Jul 31, 2017-$1.25M–
Q2 FY2017CQ1 2017Apr 30, 2017-$1.08M–
Q1 FY2017CQ4 2016Jan 31, 2017-$729.91K–
Q4 FY2016CQ3 2016Oct 31, 2016-$682.99K–

More Anixa Biosciences figures

See a number that looks wrong?